eli lilly glp-1 receptor agonist medications Big news in obesity medicine 👇 A new medication, Foundayo (orforglipron) from Lilly, is making headlines as a once-daily oral agonist. Unlike many current options that require injections, Foundayo Drugmaker Eli Lilly announced that

Positive trial outcomes coupled with significant funding into research and development will contribute towards the swift growth of this category in the coming years

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

doi: 10.2337/dc23-1287 [DOI] [PMC free article] [PubMed] [Google Scholar] 214.Bossart M, Wagner M, Elvert R, et al

21 Paragraph IV certifications are challenges to existing FDA-listed brand-name patents that are brought by generic manufacturers seeking approval of products before these patents expire

Studies show that patients tend to regain weight when treatment stops, which is why maintaining weight loss after tirzepatide requires sustained lifestyle changes

Another study indicates that starting treatment with a lower dose and gradually increasing it helped reduce the incidence of gastrointestinal adverse events [64]